Trial · NCT01259297
Participant flow48
How many started, completed or left each group, period by period.
21 to 40 of 48
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Run-in Open Label Period (4-5 Weeks) | NOT COMPLETED | HCTZ + Placebo for Aliskiren | 0 | |
| Run-in Open Label Period (4-5 Weeks) | NOT COMPLETED | Placebo for Aliskiren + Placebo for HCTZ | 0 | |
| Run-in Open Label Period (4-5 Weeks) | NOT COMPLETED | Amlodipine + Placebo for Aliskiren | 0 | |
| Run-in Open Label Period (4-5 Weeks) | NOT COMPLETED | Placebo for Aliskiren + Placebo for Amlodipine | 0 | |
| Double Blind Randomized Period | STARTED | Aliskiren + Hydrochlorothiazide (HCTZ) | 244 | |
| Double Blind Randomized Period | STARTED | Aliskiren + Placebo for HCTZ | 232 | |
| Double Blind Randomized Period | STARTED | Aliskiren + Amlodipine | 189 | |
| Double Blind Randomized Period | STARTED | Aliskiren + Placebo for Amlodipine | 195 | |
| Double Blind Randomized Period | STARTED | HCTZ + Placebo for Aliskiren | 251 | |
| Double Blind Randomized Period | STARTED | Placebo for Aliskiren + Placebo for HCTZ | 253 | |
| Double Blind Randomized Period | STARTED | Amlodipine + Placebo for Aliskiren | 196 | |
| Double Blind Randomized Period | STARTED | Placebo for Aliskiren + Placebo for Amlodipine | 199 | |
| Double Blind Randomized Period | COMPLETED | Aliskiren + Hydrochlorothiazide (HCTZ) | 242 | |
| Double Blind Randomized Period | COMPLETED | Aliskiren + Placebo for HCTZ | 229 | |
| Double Blind Randomized Period | COMPLETED | Aliskiren + Amlodipine | 188 | |
| Double Blind Randomized Period | COMPLETED | Aliskiren + Placebo for Amlodipine | 191 | |
| Double Blind Randomized Period | COMPLETED | HCTZ + Placebo for Aliskiren | 247 | |
| Double Blind Randomized Period | COMPLETED | Placebo for Aliskiren + Placebo for HCTZ | 245 | |
| Double Blind Randomized Period | COMPLETED | Amlodipine + Placebo for Aliskiren | 190 | |
| Double Blind Randomized Period | COMPLETED | Placebo for Aliskiren + Placebo for Amlodipine | 196 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01259297/flow?page=2